Attention Deficit Hyperactivity Disorder (ADHD) - Drug Pipeline Landscape, 2023

Attention Deficit Hyperactivity Disorder (ADHD) is a mental health condition that can cause unusual levels of hyperactivity and impulsive behaviours. People with ADHD may also have trouble focusing their attention on a single task or sitting still for long periods of time.

Attention deficit hyperactivity disorder caused by reduction in dopamine which is a chemical in the brain that helps move signals from one nerve to another and plays a role in triggering emotional responses and movements.

Signs and symptoms of Attention deficit hyperactivity disorder includes having trouble focusing or concentrating on tasks, being forgetful about completing tasks, being easily distracted, having difficulty sitting still, interrupting people while they’re talking and talk excessively.

Doctors most often diagnose attention deficit hyperactivity disorder based on the presence of persistent symptoms that have occurred over a period and are noticeable over the past six months.

The most common investigative treatments include behavioral therapies, medication, and psychotherapy. Central nervous system (CNS) stimulants are the most prescribed ADHD medications. Symptoms can be eased through lifestyle changes and home remedies like eating a nutritious, balanced diet.

Report Highlights

Global Insight Service’s, Attention Deficit Hyperactivity Disorder (ADHD) - Drug Pipeline Landscape, 2023 report provides an overview of the Attention Deficit Hyperactivity Disorder (ADHD) pipeline drugs. This report covers detailed insights on Attention Deficit Hyperactivity Disorder (ADHD) drugs under development, assessment by target, mechanism of action, route of administration and molecule type.Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Attention Deficit Hyperactivity Disorder (ADHD) pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.

Reasons to Buy

Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.

Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.

Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.

Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.